Related Experiment Video
Updated: Mar 7, 2026

06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
3.6K
Striatal dysfunction in X-linked dystonia-parkinsonism is associated with disease progression
N Brüggemann1,2, R L Rosales3, J L Waugh4,5
1Department of Neurology, University of Lübeck, Lübeck, Germany.
European Journal of Neurology
|February 26, 2017
Summary
X-linked dystonia-parkinsonism (XDP) involves striatal atrophy and impaired dopamine signaling. This study shows reduced post-synaptic dopamine function correlates with disease progression, indicating striatal dysfunction causes XDP symptoms.
Area of Science:
- Neuroscience
- Genetics
- Radiology
Background:
- X-linked dystonia-parkinsonism (XDP) is an inherited neurodegenerative disorder affecting the basal ganglia.
- Striatal atrophy is a hallmark of XDP, but the role of the dopaminergic system in parkinsonism is not fully understood.
Purpose of the Study:
- To investigate pre- and post-synaptic dopaminergic function in patients with XDP.
- To determine if nigrostriatal dysfunction contributes to parkinsonism in XDP.
Main Methods:
- Dopamine transporter (DAT) imaging using ioflupane (FP-CIT) SPECT.
- Dopamine D2/D3 receptor imaging using 123Iodine-benzamide (IBZM) SPECT.
- Structural MRI was performed on patients and healthy controls.
Main Results:
- IBZM SPECT revealed reduced post-synaptic dopamine receptor uptake in the caudate nucleus and putamen in 8/9 symptomatic XDP patients.
- Reduced IBZM binding correlated with longer disease duration.
- FP-CIT SPECT showed slightly reduced dopamine transporter uptake, potentially related to basal ganglia volume loss.
Conclusions:
- Functional decline in post-synaptic dopaminergic neurotransmission is linked to disease duration and neurodegeneration in XDP.
- Striatal dysfunction, evidenced by cell loss, is likely the primary cause of both parkinsonism and dystonia in XDP.
Keywords:
DYT3 dystoniaIBZM SPECTX-linked dystonia-parkinsonismdopamine transporter imagingneurogeneticsMore Related Videos
Related Concept Videos
Parkinson's Disease: Overview
2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Neural Regulation
43.9K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.9K
Lysosomal Hydrolases
4.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.7K
Satellite Stem Cells and Muscular Dystrophy
2.5K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.5K

